When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.